EU Pharmaceuticals: Weekly US Vaccine Tracker (IQVIA/Symphony)

Research evidence excerpt

EU Pharmaceuticals: Weekly US Vaccine Tracker (IQVIA/Symphony)

Deutsche Bank

Research

Europe Industry Date

North America 18 May 2026

EU Pharmaceuticals

Pharmaceuticals Periodical

Pharmaceuticals

Weekly US Vaccine Tracker (IQVIA/

Symphony)

Emmanuel Papadakis, Ph.D., CFA

Summary takes Research Analyst

To track weekly US vaccine trends with greater granularity, we present weekly +44-20-754-18522

sales/prescription data for key vaccine products, which is up to 08th May 2026, with

Niall Alexander

NRx/TRx data released on Friday and NBRx data released Monday afternoon. Research Analyst

+44-20-754-12185

n We continue to report COVID/flu data in our vaccines tracker and provide

prescription data for pediatric vaccines (including boosters and MMR), Henrietta Boeg

meningitis/pneumococcal and cervical/HPV vaccines as they relate to Research Associate

GSK and SAN (and competitors MRK and PFE). +44-20-754-10119

Kate Farrelly

n Notable highs/lows/trend shifts this week: Seasonal vaccines are

declining in line with seasonal trends. Research Associate

Shashindra Seresinhe

US weekly sales/prescription trends Research Associate

Data in the charts is sourced from IQVIA (SMART US Weekly database) and

captures weekly prescription volume units and USD sales across key channels in Supun Ukwatta

the US, including (but not limited to) clinics, long-term care, non-federal hospitals, Research Associate

chain stores, food stores and federal facilities.

In terms of the brands for companies in our coverage inside this tracker: we focus Notes for this week's tracker: Tracking of

on key products by GSK (Fluarix, Flulaval, Priorix, Boostrix, Infranrix/Pediarix, prescription dynamics for COVID-19

vaccines has inherent limitations due to